Top Industry Leaders in the ACE Inhibitors Market
Latest ACE Inhibitors Companies Update:
Pfizer (US) Focused on promoting their ACE inhibitor Accuretic® (quinapril/hydrochlorothiazide) for its proven efficacy in managing hypertension and heart failure. Partnered with healthcare providers to implement medication adherence programs for patients taking ACE inhibitors.
Novartis (Switzerland) Received FDA approval for Entresto® (sacubitril/valsartan) to treat heart failure with reduced ejection fraction, offering an alternative to traditional ACE inhibitors. Continued research on Entresto® for expanding its use in other cardiovascular conditions.
AstraZeneca (UK) Emphasized the safety and efficacy of their ACE inhibitor Altace® (ramipril) for hypertension and heart failure, highlighting its long-standing presence in the market. Collaborated with research institutions to explore new applications of ACE inhibitors for neurodegenerative diseases.
Teva Pharmaceutical Industries (Israel) Leveraged their strong position in generic drug manufacturing to offer affordable ACE inhibitor options, increasing market accessibility. Focused on developing innovative drug delivery systems for ACE inhibitors to improve patient compliance and enhance medication effectiveness.
American Heart Association (AHA) Updated their clinical practice guidelines for hypertension management, emphasizing the continued relevance of ACE inhibitors as a first-line treatment option for many patients. Provided educational resources and patient advocacy programs to raise awareness about hypertension and importance of medication adherence.
List of ACE Inhibitors Key companies in the market
-
Pfizer Inc.
-
AstraZeneca Pharmaceutical Company
-
Novartis AG
-
Johnson and Johnson Services
-
United Therapeutics Corporation
-
Merck KGaA
-
Teva Pharmaceutical Industry
-
Sandoz AG
-
Novartis AG
-
Bayer AG
-
Sanofi